Peptides Promise Longevity and Healing. Does the Science Back Them Up?
A science-journalism examination of the peptide wellness boom finds that most popularly used compounds — including BPC-157, GHK-Cu, and ipamorelin — have limited clinical evidence despite widespread promotion by influencers and biohacking communities. The article notes that in 2023 the FDA barred US compounding pharmacies from producing several of these peptides, including BPC-157, GHK-Cu, and ipamorelin, citing significant safety risks, pushing many users toward unregulated overseas suppliers.
This is a summary. The reporting is Scientific American's, and the link below goes to the original article.